タナカ　ジユンジ   TANAKA Junji   田中　淳司    所属   その他 その他    職種   非常勤嘱託
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Circulating cell-free DNA in the peripheral blood plasma of patients is an informative biomarker for multiple myeloma relapse.
掲載誌名	正式名：International journal of clinical oncology 略　 称：Int J Clin Oncol ISSNコード：14377772/13419625
掲載区分	国外
巻・号・頁	26(11),pp.2142-2150
著者・共著者	Yasui Hiroshi†, Kobayashi Masayuki, Sato Kota, Kondoh Kanya, Ishida Tadao, Kaito Yuta, Tamura Hideto, Handa Hiroshi, Tsukune Yutaka, Sasaki Makoto, Komatsu Norio, Tanaka Norina, Tanaka Junji, Kizaki Masahiro, Kawamata Toyotaka, Makiyama Junya, Yokoyama Kazuaki, Imoto Seiya, Tojo Arinobu, Imai Yoichi
発行年月	2021/11
概要	BACKGROUND:Multiple myeloma (MM) is an incurable hematological malignancy. Despite the introduction of several novel drugs, most patients relapse. Biomarkers to identify the early signs of relapse will make it possible to adjust the therapeutic strategy before the disease worsens. Although understanding genetic changes is important for the treatment of MM, currently known biomarkers of relapse, including serum free-light chains and monoclonal paraproteins, are not associated with genetic changes.METHODS:We therefore performed a multicenter study to examine the usefulness of circulating cell-free DNA (cfDNA) present in the peripheral blood (PB) plasma of patients as a biomarker for MM relapse.RESULTS:We identified several driver mutations by combined analysis of next-generation sequencing and existing databases of candidate oncogenes. Furthermore, relapse was detected more sensitively by monitoring the circulating cfDNA with these driver mutations than by conventional serum free-light chain examination.CONCLUSION:These results suggest the potential utility of cfDNA in the PB plasma of patients as a relevant early biomarker for MM relapse.
DOI	10.1007/s10147-021-01991-z
PMID	34259983